Merck's Keytruda inches toward another biomarker-based OK with latest priority review

7th April 2020 Uncategorised 0

Merck & Co.’s immuno-oncology competitors have tried, so far fruitlessly, to use the investigational biomarker tumor mutational burden to help them win approvals. But regulators apparently like what they’re seeing from Merck where TMB is concerned.

More: Merck's Keytruda inches toward another biomarker-based OK with latest priority review
Source: fierce